A recent study has revealed that Sotagliflozin, a drug approved by the US Food and Drug Administration (FDA) for treating type 2 diabetes, can also significantly lower the risk of heart attacks and strokes. This finding came from an international clinical trial that involved over 10,000 participants and highlighted the drug’s additional benefits in reducing...
